- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 4: The FDA Takes Initiative to Regulate the Diagnostic Test Market
Daniel F. Hayes, MD, discusses the FDA's announcement that it will begin to regulate laboratory-developed tests and his belief that it will not squash innovation in the field.
John Fox, MD, MHA, wondered if the FDA’s announcement that it will begin to regulate laboratory-developed tests being marketed will limit the number of people who develop tests and help clean up the market.
Daniel F. Hayes, MD, hopes that will be the case and he is happy with the FDA initiative and how responsibly the agency has approached beginning to regulate the field.
“There’s a great deal of concern that this will squash innovation and dampen down new test development,” he said. “I think it might have the opposite [effect].”
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
